NEW YORK – Opus Genetics has enrolled the final patient into its registrational Phase III clinical trial evaluating its investigational gene therapy for a severe, inherited retinal dystrophy, the ...
NEW YORK – Rocket Pharmaceuticals is discussing next steps to complete a pivotal Phase II trial of its Danon disease gene therapy, RP-A501, with the US Food and Drug Administration based on promising ...
The firm's personalized immunotherapy DISP-10 combines an engineered tumor-specific virus with BMS's CAR T-cell therapy Abecma.
The network of community oncology practices eventually hopes to integrate the tool with its genomic databases.
NEW YORK – The American Association for Cancer Research on Wednesday announced the launch a Phase II trial testing precision medicines that would allow patients with locally advanced gastroesophageal ...
NEW YORK – As Verastem Oncology's approved product Avmapki Fakzynja Co-Pack (avutometinib and defactinib) is hitting its stride in ovarian cancer, the firm is turning its attention to its KRAS G12D ...
NEW YORK – Intellia Therapeutics is preparing commercial launch activities for its CRISPR gene-editing treatment for hereditary angioedema (HAE), lonvoguran ziclumeran. Intellia initiated in the ...
Overall, the firm's sales were up 10 percent and beat Wall Street expectations, but net income took a hit from recent ...
NEW YORK – Hangzhou, China-based CellOrigin has enlisted Walvax Biotechnology to help launch an investigator-initiated trial testing an in vivo GPC3-targeted CAR therapy in patients with ...
The firm disclosed the update on the gene therapy, which it acquired in its 2021 purchase of Prevail Therapeutics, in its Q2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results